Page last updated: 2024-10-30

lomustine and Lymphoma, T-Cell

lomustine has been researched along with Lymphoma, T-Cell in 8 studies

Lymphoma, T-Cell: A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.

Research Excerpts

ExcerptRelevanceReference
"Lomustine, vincristine, procarbazine and prednisolone (LOPP) chemotherapy has been suggested to be an effective treatment for dogs with naïve non-indolent T-cell lymphoma (TCL)."8.12Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy. ( Blaxill, J; Buzzacott, P; Finlay, J, 2022)
" The objective of the present study was to investigate if a shorter protocol combined with an oral lomustine maintenance treatment (3 × in 8 weeks) would present an acceptable result, both for B- and T-cell lymphomas, and for the different types of lymphomas normally encountered in private veterinary practice."8.12Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma. ( Eberle, N; Limmer, S; Nerschbach, V; Simon Betz, D; Teske, E, 2022)
"Multi-agent chemotherapy (vincristine, epirubicin and prednisolone) including either cyclophosphamide (CEOP) or lomustine (LEOP) was given as first-line chemotherapy to treatment-naïve canine lymphoma patients with measurable, high grade T-cell lymphoma (HGTCL)."7.91A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017). ( Baines, S; Elliott, J, 2019)
"Lomustine, vincristine, procarbazine and prednisolone (LOPP) chemotherapy has been suggested to be an effective treatment for dogs with naïve non-indolent T-cell lymphoma (TCL)."4.12Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy. ( Blaxill, J; Buzzacott, P; Finlay, J, 2022)
" The objective of the present study was to investigate if a shorter protocol combined with an oral lomustine maintenance treatment (3 × in 8 weeks) would present an acceptable result, both for B- and T-cell lymphomas, and for the different types of lymphomas normally encountered in private veterinary practice."4.12Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma. ( Eberle, N; Limmer, S; Nerschbach, V; Simon Betz, D; Teske, E, 2022)
"Multi-agent chemotherapy (vincristine, epirubicin and prednisolone) including either cyclophosphamide (CEOP) or lomustine (LEOP) was given as first-line chemotherapy to treatment-naïve canine lymphoma patients with measurable, high grade T-cell lymphoma (HGTCL)."3.91A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017). ( Baines, S; Elliott, J, 2019)
"The aim of this study was to describe the use of a lomustine (CCNU), vincristine, procarbazine and prednisolone (LOPP) protocol used for treatment of chemotherapy naive T-cell lymphoma patients and to describe the response rate, toxicity and disease-free interval compared historically to CHOP chemotherapy."3.88LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma. ( Brown, PM; Langova, V; Nguyen, S; Tzannes, S; White, J, 2018)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (25.00)18.2507
2000's0 (0.00)29.6817
2010's3 (37.50)24.3611
2020's3 (37.50)2.80

Authors

AuthorsStudies
Blaxill, J1
Buzzacott, P1
Finlay, J1
Limmer, S2
Nerschbach, V2
Eberle, N2
Teske, E2
Simon Betz, D2
Purzycka, K1
Peters, LM1
Desmas, I1
Davies, O1
Chang, YM1
Lara-Garcia, A1
Brown, PM1
Tzannes, S1
Nguyen, S1
White, J1
Langova, V1
Morgan, E1
O'Connell, K1
Thomson, M1
Griffin, A1
Elliott, J1
Baines, S1
Gong, Y1
Liang, R1
Chiu, E1
Chan, TK1
Todd, D1
Loke, SL1

Trials

1 trial available for lomustine and Lymphoma, T-Cell

ArticleYear
Radiotherapy of midline malignant reticulosis.
    Chinese medical journal, 1995, Volume: 108, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Lomustine

1995

Other Studies

7 other studies available for lomustine and Lymphoma, T-Cell

ArticleYear
Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy.
    Veterinary and comparative oncology, 2022, Volume: 20, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Hypercalcemia; Lomustin

2022
Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma.
    Acta veterinaria Scandinavica, 2022, Dec-12, Volume: 64, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Lomustine; Lymphoma; Ly

2022
Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma.
    Acta veterinaria Scandinavica, 2022, Dec-12, Volume: 64, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Lomustine; Lymphoma; Ly

2022
Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma.
    Acta veterinaria Scandinavica, 2022, Dec-12, Volume: 64, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Lomustine; Lymphoma; Ly

2022
Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma.
    Acta veterinaria Scandinavica, 2022, Dec-12, Volume: 64, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Lomustine; Lymphoma; Ly

2022
Clinicopathological characteristics and prognostic factors for canine multicentric non-indolent T-cell lymphoma: 107 cases.
    Veterinary and comparative oncology, 2020, Volume: 18, Issue:4

    Topics: Animals; Antineoplastic Agents, Alkylating; Disease Progression; Dog Diseases; Dogs; Lomustine; Lymp

2020
LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma.
    Veterinary and comparative oncology, 2018, Volume: 16, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Female; Lomustine; Lymp

2018
Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs.
    Veterinary and comparative oncology, 2018, Volume: 16, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dog Diseases; Dogs;

2018
A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017).
    Australian veterinary journal, 2019, Volume: 97, Issue:9

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Horm

2019
Direct comparison of peripheral T-cell lymphomas with their B-cell counterpart.
    Acta haematologica, 1991, Volume: 85, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; China; Cyclophosphamide; Dexamethasone; D

1991